Faculty Bios

To proceed to the next module, CLICK HERE

Chairperson 

Steven J. Cohen, MD
Chief of GI Medical Oncology
Co-Leader of the GI Cancer Service Line
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Steven Cohen, MD, is Chief of Gastrointestinal Medical Oncology and Co-Leader of the Gastrointestinal Cancer Service Line at Fox Chase Cancer Center in Philadelphia, Pennsylvania.  In addition to his GI cancer responsibilities, Dr. Cohen serves as the Program Director for the Temple University Hospital/Fox Chase Cancer Center hematology/oncology fellowship program. He also is Chief Medical Officer for Fox Chase Cancer Center Partners, overseeing medical oncology at affiliated hospitals within the Fox Chase network.

He is a member of National Comprehensive Cancer Network Pancreatic Adenocarcinoma Guidelines Committee; the Eastern Cooperative Oncology Group where he is the representative on the National Cancer Institute Pancreatic Cancer Task Force; the American Society of Clinical Oncology where he is also a member of the Test Materials Development Committee, and a member of the Scientific Program Committee, Gastrointestinal (Colorectal) Cancer Track.  

He is an active member of the Eastern Cooperative Group of Oncology (ECOG) Gastrointestinal Committee, ECOG representative to the National Cancer Institute (NCI) Pancreatic Cancer Task Force, and serves on the American Society of Clinical Oncology Scientific Program Committee in GI Cancer (colorectal) and is a member of the Test Materials Development Committee. In 2010, he received the NCI Clinical Investigator Team Leadership Award and in 2013, he graduated from the ASCO Leadership Development Program.  Dr. Cohen is on the editorial board for the Journal of Gastrointestinal Cancer and is a peer reviewer for Cancer Chemotherapy and Pharmacology, International Journal of Cancer, Clinical Cancer Research, Journal of Clinical Oncology, Oncology, Cancer, Clinical Colorectal Cancer, Clinical Advances in Hematology and Oncology, Expert Opinion on Drug Discovery, Journal of the National Comprehensive Cancer Network, Annals of Oncology, and Annals of Surgical Oncology.  He received his Doctor of Medicine degree from State University of New York at Stony Brook.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant:

Steven J. Cohen, MD, reported a financial interest/relationship or affiliation in the form of: consulting fee, Celgene Corporation, Merrimack Pharmaceuticals.

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Linda Gracie-King, MS; Deborah Middleton, MS; and Jocelyn Timko, BS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.


Faculty 

Jordan D. Berlin, MD
Ingram Professor of Cancer Research
Professor of Medicine
Clinical Director, GI Oncology Program
Director, Phase I Program
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Jordan D. Berlin, MD, is Ingram Professor of Cancer Research and Professor of Medicine at Vanderbilt University in Nashville, Tennessee.  He is also Director of the Clinical Gastrointestinal Program at Vanderbilt-Ingram Cancer Center.  His clinical research efforts focus on novel treatment approaches to treat gastrointestinal cancers such as malignancies of the colon, rectum, anus, esophagus, stomach, small intestine, liver, gallbladder, pancreas and bile ducts. 

Dr. Berlin is an editorial board member for the International Journal of GI Cancer and is Editor-in-Chief for Colorectal Cancer Index and Reviews.  He is also currently a member of the American Association for Cancer Research; the American Society of Clinical Oncology where he is also Co-Chair of the Clinically Meaningful Outcomes in Pancreatic Cancer Subcommittee; the Eastern Cooperative Oncology Group where he is the representative on the Intergroup Task Force on Pancreatic Cancer and Core Committee Member of the Laboratory Sciences Subcommittee; the International Society of GI Oncology; the European Society of Medical Oncology; and the North American Neuroendocrine Tumor Society.  Dr. Berlin received his Doctor of Medicine degree from the University of Illinois in Chicago, completed his residency in Internal Medicine at the University of Cincinnati Hospital in Cincinnati, Ohio, and his fellowship in Medical Oncology at the University of Wisconsin Hospital and Clinics in Madison, Wisconsin.    

DISCLOSURE OF CONFLICTS OF INTEREST

Jordan Berlin, MD, reported a financial interest/relationship or affiliation in the form of: consulting fee, Celgene Corporation, Genentech, Inc., Ipsen, Novartis Pharmaceuticals Corporation, Symphogen, Vertex Pharmaceuticals; contracted research, AbbVie, Genentech, Inc., Gilead, Immunomedics, Inc., Lilly USA, Novartis Pharmaceuticals Corporation, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Taiho Pharmaceutical Co., Ltd.


Weijing Sun, MD, FACP
Professor of Medicine
Director of the Gastrointestinal Cancer Disease Section
University of Pittsburgh School of Medicine
Co-Director of the University of Pittsburgh Medical Center
Gastrointestinal Cancer Center of Excellence
Pittsburgh, Pennsylvania

Weijing Sun, MD, FACP, is a Medical Oncologist, Professor of Medicine, Director of the Gastrointestinal Cancer Disease Section in the Division of Hematology-Oncology, and Co-Director of the University of Pittsburgh Medical Center Gastrointestinal Cancer Center of Excellence in Pennsylvania. 

Dr. Sun is a member of the American Medical Association, the American Society of Clinical Oncology, the American Association of Cancer Research, the Eastern Cooperative Group of Oncology Gastrointestinal Cancer Core Committee, the American College of Physicians – Internal Medicine, the National Cancer Institute Gastrointestinal Cancer Steering Committee Hepatobiliary Task Force, and serves on the American Society of Clinical Oncology Scientific Program and Membership Committee. In addition, Dr. Sun has been recognized on U.S. News & World Report’s American Top Doctors list.

Dr. Sun has authored many publications, including original clinical research articles, reviews, and invited editorial comments in a variety of peer-reviewed journals. He has also written chapters as a GI oncology expert for several medical textbooks, including WebMD and Textbook of Gastroenterology. Dr. Sun has had more than 70 publications.  He is a member of the editorial board and review committee for several professional journals, including Clinical Colorectal Cancer, Journal of Clinical Gastroenterology, Journal of Clinical Oncology, Cancer, Disease of the Colon and Rectum, Cancer Biology and Therapy, Expert Opinion on Investigational Drugs, Pharmacogenomics, Gastroenterology, Expert Review of Anticancer Therapy, and American Journal of Hematology-Oncology.  Dr. Sun received his Doctor of Medicine degree from Shanghai Medical College, Fudan University, in Shanghai. He completed his residency in internal medicine at Loyola University Medical Center in Maywood, Illinois, and his hematology-oncology fellowship at the University of Pennsylvania in Philadelphia.

DISCLOSURE OF CONFLICTS OF INTEREST

Weijing Sun, MD, FACP, reported a financial interest/relationship or affiliation in the form of: consulting fee, Celgene Corporation.

To proceed to the next module, CLICK HERE